[{"id":"e704c4fd-c7ac-4597-8954-effccdbd050f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949944","created_at":"2023-07-20T15:09:21.771Z","updated_at":"2024-07-02T16:35:02.840Z","phase":"Phase 1/2","brief_title":"Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT05949944","lead_sponsor":"Sun Yat-sen University","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 expression • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 expression • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Itari (linperlisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-17"},{"id":"cc25bfa5-9472-407a-87d6-85aeca7b68d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06324994","created_at":"2024-03-22T23:35:39.141Z","updated_at":"2024-07-02T16:35:13.272Z","phase":"Phase 2","brief_title":"Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.","source_id_and_acronym":"NCT06324994","lead_sponsor":"Dalian Medical University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Itari (linperlisib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-22"},{"id":"6cf28ab6-c200-4973-a27b-a9bc1c50c07a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05274997","created_at":"2022-03-11T15:53:34.103Z","updated_at":"2024-07-02T16:36:02.074Z","phase":"Phase 2","brief_title":"A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma","source_id_and_acronym":"NCT05274997","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Itari (linperlisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-10-21"},{"id":"13198163-cd48-47a3-bea2-26ce7352937f","acronym":"YY-20394-002","url":"https://clinicaltrials.gov/study/NCT04370405","created_at":"2021-01-18T21:07:01.254Z","updated_at":"2024-07-02T16:36:45.187Z","phase":"Phase 2","brief_title":"A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04370405 - YY-20394-002","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Itari (linperlisib)"],"overall_status":"Unknown status","enrollment":" Enrollment 123","initiation":"Initiation: 04/29/2019","start_date":" 04/29/2019","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 02/22/2021","study_completion_date":" 02/22/2021","last_update_posted":"2020-05-11"}]